Brendon Kearney - Panel Session - HealthPACT: Choosing The Right Assessment Method For Non-Drug...
-
Upload
informa-australia -
Category
Health & Medicine
-
view
398 -
download
0
Transcript of Brendon Kearney - Panel Session - HealthPACT: Choosing The Right Assessment Method For Non-Drug...
![Page 1: Brendon Kearney - Panel Session - HealthPACT: Choosing The Right Assessment Method For Non-Drug Technologies: Observational Studies vs. Randomised Control Trials (RCT)](https://reader034.fdocuments.in/reader034/viewer/2022042906/58ab228b1a28abb5278b58bf/html5/thumbnails/1.jpg)
The use of observational data in health economic models of medical devices: science, art or both?
Professor Brendon Kearney
Australia
![Page 2: Brendon Kearney - Panel Session - HealthPACT: Choosing The Right Assessment Method For Non-Drug Technologies: Observational Studies vs. Randomised Control Trials (RCT)](https://reader034.fdocuments.in/reader034/viewer/2022042906/58ab228b1a28abb5278b58bf/html5/thumbnails/2.jpg)
Australian HTA agencies
TGA
PBAC
MSAC
Protheses & Devices Ctte
Health PACT
![Page 3: Brendon Kearney - Panel Session - HealthPACT: Choosing The Right Assessment Method For Non-Drug Technologies: Observational Studies vs. Randomised Control Trials (RCT)](https://reader034.fdocuments.in/reader034/viewer/2022042906/58ab228b1a28abb5278b58bf/html5/thumbnails/3.jpg)
Drugs
PBAC
Clinical trials
Reimbursement
![Page 4: Brendon Kearney - Panel Session - HealthPACT: Choosing The Right Assessment Method For Non-Drug Technologies: Observational Studies vs. Randomised Control Trials (RCT)](https://reader034.fdocuments.in/reader034/viewer/2022042906/58ab228b1a28abb5278b58bf/html5/thumbnails/4.jpg)
AAA Stenting
Interim funding subject to data collection by RACS
ASERNIPS funded to collect data
Results compared with RCT
Full funding implemented
![Page 5: Brendon Kearney - Panel Session - HealthPACT: Choosing The Right Assessment Method For Non-Drug Technologies: Observational Studies vs. Randomised Control Trials (RCT)](https://reader034.fdocuments.in/reader034/viewer/2022042906/58ab228b1a28abb5278b58bf/html5/thumbnails/5.jpg)
Deep Brian Stimulation Parkinsons Dystonia Essential tremor
No trials but case serries
Interim funded
Data collection from 4 sites
RCTs published
Full funding
![Page 6: Brendon Kearney - Panel Session - HealthPACT: Choosing The Right Assessment Method For Non-Drug Technologies: Observational Studies vs. Randomised Control Trials (RCT)](https://reader034.fdocuments.in/reader034/viewer/2022042906/58ab228b1a28abb5278b58bf/html5/thumbnails/6.jpg)
Capsule Endoscopy
Case series only
MSAC funded an evaluation based on operator data collection
Data collection and report considered poor but MSAC felt it could not recommend withdrawal of funding
Implementation managed with description of service use
![Page 7: Brendon Kearney - Panel Session - HealthPACT: Choosing The Right Assessment Method For Non-Drug Technologies: Observational Studies vs. Randomised Control Trials (RCT)](https://reader034.fdocuments.in/reader034/viewer/2022042906/58ab228b1a28abb5278b58bf/html5/thumbnails/7.jpg)
PET Scanning
Interim funding for several indications subject to data collection agreed to by ANZAPAM
Very few RCTs
Data collection not helpful
Worldwide roll out
Funding for a number of indications with restrictions
Some but not enough RCTs
Cost of HTA versus service
![Page 8: Brendon Kearney - Panel Session - HealthPACT: Choosing The Right Assessment Method For Non-Drug Technologies: Observational Studies vs. Randomised Control Trials (RCT)](https://reader034.fdocuments.in/reader034/viewer/2022042906/58ab228b1a28abb5278b58bf/html5/thumbnails/8.jpg)
BNP assay
One fair quality RCT
Limited to emergency department
Funded but with restrictions
Indication creep
![Page 9: Brendon Kearney - Panel Session - HealthPACT: Choosing The Right Assessment Method For Non-Drug Technologies: Observational Studies vs. Randomised Control Trials (RCT)](https://reader034.fdocuments.in/reader034/viewer/2022042906/58ab228b1a28abb5278b58bf/html5/thumbnails/9.jpg)
Hyperbaric O2
Interim funding for broad indications
Review
Lack of RCTs led to restriction in indications
![Page 10: Brendon Kearney - Panel Session - HealthPACT: Choosing The Right Assessment Method For Non-Drug Technologies: Observational Studies vs. Randomised Control Trials (RCT)](https://reader034.fdocuments.in/reader034/viewer/2022042906/58ab228b1a28abb5278b58bf/html5/thumbnails/10.jpg)
High Sensitivity Troponin Sensitivity Specificity
Used in the same way but lower cut offs
RCT – three groups
1. Acute Coronary Syndrome
with high risk of major cardiac event
2. ACS with risk of MCE
greater than one month
3. Negative for ACS
RCT required to use new technology for best outcomes from patient care
![Page 11: Brendon Kearney - Panel Session - HealthPACT: Choosing The Right Assessment Method For Non-Drug Technologies: Observational Studies vs. Randomised Control Trials (RCT)](https://reader034.fdocuments.in/reader034/viewer/2022042906/58ab228b1a28abb5278b58bf/html5/thumbnails/11.jpg)
Tavi
Not on ARTG
SAS or CTN approval
Used in patients unsuitable for cardiac surgery
Ethics approval but no coordinated implementation
Variation in rate
Small numbers in some units
![Page 12: Brendon Kearney - Panel Session - HealthPACT: Choosing The Right Assessment Method For Non-Drug Technologies: Observational Studies vs. Randomised Control Trials (RCT)](https://reader034.fdocuments.in/reader034/viewer/2022042906/58ab228b1a28abb5278b58bf/html5/thumbnails/12.jpg)
Need to manage introduction of new technologies where there is:
high cost
high volume
patient safety and outcomes
1. RCT
2. Managed introduction with evaluation
![Page 13: Brendon Kearney - Panel Session - HealthPACT: Choosing The Right Assessment Method For Non-Drug Technologies: Observational Studies vs. Randomised Control Trials (RCT)](https://reader034.fdocuments.in/reader034/viewer/2022042906/58ab228b1a28abb5278b58bf/html5/thumbnails/13.jpg)
Lessons
Possible but data has to be good quality
Funding of data collection
Data collection quality
Currently not supported